CA57384M1077
© Newsfile
03.02.2026
MRVL
LISTED
TSX
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to anno...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Grant of Deferred Share Units
News Preview
Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs...
Themefolio
Profiler
Peergroup
© Newsfile
03.10.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
News Preview
Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
18.08.2025
MRVL
LISTED
TSX
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
12.08.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Grant of Deferred Share Units
News Preview
Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees.The DSUs will all ves...
Themefolio
Profiler
Peergroup
© Newsfile
13.05.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Closing of Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces that, further to its press releases of March 28, 2025 and May 2, 2025, it has closed its non-brokered private placement (the "Offering"). Pursuant t...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the...
Themefolio
Profiler
Peergroup
© Newsfile
30.04.2025
MRVL
LISTED
TSX
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
News Preview
Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le M...
Themefolio
Profiler
Peergroup
© Newsfile
16.04.2025
MRVL
LISTED
TSX
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
News Preview
Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-1...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2025
MRVL
LISTED
TSX
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conferen...
Themefolio
Profiler
Peergroup
© Newsfile
28.03.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the first tranche of a non-brokered private placemen...
Themefolio
Profiler
Peergroup
© Newsfile
17.03.2025
MRVL
LISTED
TSX
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
News Preview
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-20...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
13.03.2025
MRVL
LISTED
TSX
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
News Preview
Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute....
Themefolio
Profiler
Peergroup
© Newsfile
11.03.2025
MRVL
LISTED
TSX
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the "Conferenc...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
News Preview
Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce that the Chinese patent office has issued a notice of allowance for its lead compound MB-204. This is the firs...
Themefolio
Profiler
Peergroup
© Newsfile
07.01.2025
MRVL
LISTED
TSX
Marvel Biosciences Announces Private Placement for up to $2.5 Million
News Preview
Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company (each a "Common Share") at a price of $0.15 per Common Share for gross proceeds of a...
Themefolio
Profiler
Peergroup
© Newsfile
26.11.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
News Preview
Calgary, Alberta--(Newsfile Corp. - November 26, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), are pleased to share additional data from its ongoing preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute...
Themefolio
Profiler
Peergroup
© Newsfile
21.11.2024
MRVL
LISTED
TSX
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research
News Preview
Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the p...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome
News Preview
Calgary, Alberta--(Newsfile Corp. - November 7, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB204, as a potential new treatment for Rett syndrome. The study, conducted by e...
Themefolio
Profiler
Peergroup
© Newsfile
10.10.2024
MRVL
LISTED
TSX
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
News Preview
Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iB...
Themefolio
Profiler
Peergroup
© Newsfile
13.08.2024
MRVL
LISTED
TSX
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
News Preview
Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Stock Option Grants
News Preview
Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options") to certain directors and officers...
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2024
MRVL
LISTED
TSX
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
News Preview
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN...
Themefolio
Profiler
Peergroup
© Newsfile
19.07.2024
MRVL
LISTED
TSX
Marvel Biosciences Closes Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has closed its non-brokered private placement unit offering (th...
Themefolio
Profiler
Peergroup
© Newsfile
09.07.2024
MRVL
LISTED
TSX
Marvel Highlights New Published Research of Its SAB Member Professor David Blum
News Preview
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice" by a...
Themefolio
Profiler
Peergroup
© Newsfile
21.06.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Private Placement Update
News Preview
Calgary, Alberta--(Newsfile Corp. - June 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), wishes to announce that, further to Marvel's May 16, 2024 press release announcing the Company's non-brokered private placement unit offering (the "Offering")...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the "Units") at a price of $0.10 per Unit for gross proceeds of up...
Themefolio
Profiler
Peergroup
© Newsfile
25.03.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world e...
Themefolio
Profiler
Peergroup
© Newsfile
12.03.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, Fr...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Testing MB-204 on Autism by French University
News Preview
Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jer...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2024
MRVL
LISTED
TSX
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - January 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce the Company has closed a non-brokered private placement (the "Offering") of unsecured convertible debentures (each, a "Debenture")....
Themefolio
Profiler
Peergroup
© Newsfile
08.01.2024
MRVL
LISTED
TSX
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
News Preview
Calgary, Alberta--(Newsfile Corp. - January 8, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on T...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2023
MRVL
LISTED
TSX
Marvel Biosciences Invited to Test MB-204 on Autism by French University
News Preview
Calgary, Alberta--(Newsfile Corp. - November 16, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effec...
Themefolio
Profiler
Peergroup
© Newsfile
22.08.2023
MRVL
LISTED
TSX
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
News Preview
Calgary, Alberta--(Newsfile Corp. - August 22, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose...
Themefolio
Profiler
Peergroup
© Newsfile
10.07.2023
MRVL
LISTED
TSX
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has been selected to present the Company's scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a...
Themefolio
Profiler
Peergroup
© Newsfile
20.04.2023
MRVL
LISTED
TSX
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
News Preview
Calgary, Alberta--(Newsfile Corp. - April 20, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enablin...
Themefolio
Profiler
Peergroup
© Newsfile
21.03.2023
MRVL
LISTED
TSX
Marvel Commences Final Study Required Prior to Initiating Human Trials
News Preview
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies f...
Themefolio
Profiler
Peergroup
© Newsfile
09.03.2023
MRVL
LISTED
TSX
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
News Preview
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies fo...
Themefolio
Profiler
Peergroup
© Newsfile
24.02.2023
MRVL
LISTED
TSX
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
News Preview
Calgary, Alberta--(Newsfile Corp. - February 24, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures ("Debentures") for gross proceeds of $1,000,000 (the "Private Placement"), subj...
Themefolio
Profiler
Peergroup
© Newsfile
15.02.2023
MRVL
LISTED
TSX
Marvel Biosciences Announces Proposed Debenture Offering
News Preview
Calgary, Alberta--(Newsfile Corp. - February 15, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $1,500,000 (the "Private Placement"). The Debentures will b...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2023
MRVL
LISTED
TSX
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
News Preview
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active ph...
Themefolio
Profiler
Peergroup
© Newsfile
03.01.2023
MRVL
LISTED
TSX
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These s...
Themefolio
Profiler
Peergroup
© Newsfile
23.12.2022
MRVL
LISTED
TSX
Marvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services
News Preview
Calgary, Alberta--(Newsfile Corp. - December 23, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the "Consulting Agreement") with Mr. Ad...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2022
MRVL
LISTED
TSX
Marvel Biosciences Announces Stock Option Grant
News Preview
Calgary, Alberta--(Newsfile Corp. - December 20, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to a director to acquire 200,000 common shar...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2022
MRVL
LISTED
TSX
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
News Preview
Calgary, Alberta--(Newsfile Corp. - December 12, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204.To date, the Company's MB-204 has sho...
Themefolio
Profiler
Peergroup
© Newsfile
07.12.2022
MRVL
LISTED
TSX
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression
News Preview
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in pr...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2022
MRVL
LISTED
TSX
Marvel Biosciences Announces Director Appointment and Resignation
News Preview
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors.Babak Pedram, DirectorMr. Pedram brings a vast...
Themefolio
Profiler
Peergroup
© Newsfile
22.11.2022
MRVL
LISTED
TSX
Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
News Preview
Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of ani...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2022
MRVL
LISTED
TSX
Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies
News Preview
Calgary, Alberta--(Newsfile Corp. - November 14, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2022
MRVL
LISTED
TSX
Marvel Biosciences' Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression
News Preview
Calgary, Alberta--(Newsfile Corp. - November 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced today that in a pre-clinical mouse study conducted by the Company, its lead drug candidate MB-204 successfully entered the brain and occupied its...
Themefolio
Profiler
Peergroup
© Newsfile
01.11.2022
MRVL
LISTED
TSX
Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer's Further Advancing Towards FDA Phase I Human Trials
News Preview
Calgary, Alberta--(Newsfile Corp. - November 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2022
MRVL
LISTED
TSX
Marvel Biosciences Advances Closer to Human Trials After the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
News Preview
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company's lead drug candidate low toxicity characteristic. "We have now completed an...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2022
MRVL
LISTED
TSX
Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
News Preview
Calgary, Alberta--(Newsfile Corp. - October 17, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity.MB-204 is the Company's lead compound and is a novel fluorinated form of Istradefylline...
Themefolio
Profiler
Peergroup
© Newsfile
04.10.2022
MRVL
LISTED
TSX
Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
News Preview
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression. According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of th...
Themefolio
Profiler
Peergroup
© Newsfile
26.09.2022
MRVL
LISTED
TSX
Marvel Biosciences Announces Stock Option Grants
News Preview
Calgary, Alberta--(Newsfile Corp. - September 26, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquir...
Themefolio
Profiler
Peergroup
© Newsfile
31.08.2022
MRVL
LISTED
TSX
Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease
News Preview
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer's Disease (AD), two programs its lead asset, MB-204 are targeting.A five-year longitudinal study in Sweden tracked subjects wi...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2022
MRVL
LISTED
TSX
Marvel Biosciences Closes Second Tranche of Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 uni...
Themefolio
Profiler
Peergroup
© Newsfile
21.07.2022
MRVL
LISTED
TSX
Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset
News Preview
Calgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.The formulation involves producing a solid amorphous dispersion of MB-204 using a s...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2022
MRVL
LISTED
TSX
Marvel Biosciences Closes First Tranche of Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - July 18, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news release of June 21, 2022, it has closed the first tranche of its non-brokered private placement of 4,500,000 un...
Themefolio
Profiler
Peergroup
© Newsfile
21.06.2022
MRVL
LISTED
TSX
Marvel Biosciences Announces Non-Brokered Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - June 21, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
